Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Peginterferon alfa-2b consolidation in chronic hepatitis B
NCT06920329Not yet recruiting
- Sponsor
- Xiamen Hospital of Traditional Chinese Medicine
- Start
- Apr 2025
- Primary completion
- Dec 2027
- Modality
- Polymer-based Nanoparticles, Cytokines & Interferons
- Countries
- 1
01
Overview
Open-label trial of peginterferon alfa-2b in Chronic Hepatitis B (CHB) (2 arms), sponsored by Xiamen Hospital of Traditional Chinese Medicine. Primary endpoints: Changes in intrahepatic cccDNA levels at 48 weeks, Changes in peripheral blood pgRNA levels at 48 weeks and 1 more. Planned start Apr 2025; status: not yet recruiting.
02
Drugs
peginterferon alfa-2b
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT06920329.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06920329.